#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Osteosarcoma Osteopetrosis Prophylaxis against transplant rejection Meningitis meningococcal Superficial vein thrombosis Autoimmune demyelinating disease Pneumonia Neurodermatitis Congenital absence of bile ducts Acquired ATTR amyloidosis Antiphospholipid syndrome Neutropenia Acute respiratory distress syndrome Non-Hodgkin's lymphoma Blastic plasmacytoid dendritic cell neoplasia More trials…

    Learn about Rare Diseases

    Acquired haemophilia – Trials in Disease Glycogen storage disease type V – Diagnostics Small intestine leiomyosarcoma – Basic Information Primary hyperoxaluria – Diagnostics Breast angiosarcoma metastatic – Basic Information Inclusion body myositis – Treatment Prader-Willi syndrome – Basic Information Haemolytic uraemic syndrome – Diagnostics Lymphangiosarcoma – Trials in Disease Osteosarcoma metastatic – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ceritinib Tisotumab Vedotin Ciprofloxacin Deutivacaftor Mk-1084 Flecainide Acetate Ambrisentan Niflumic Acid Milrinone Timrepigene Emparvovec ALLERGEN EXTRACTS Lumasiran PRILOCAINE HYDROCHLORIDE Cilgavimab Lysine Hydrochloride Tamoxifen Citrate Ciclosporin Aficamten SPY002 Pyridoxine Hydrochloride More therapies…

    Learn about Your Condition

    Cerebral amyloid angiopathy Pancreatic neoplasm Microscopic polyangiitis Vulvar dysplasia Appendicitis perforated Right ventricular dysfunction Haemodynamic instability Brain neoplasm malignant Pulmonary hypertension Cachexia Choroidal neovascularisation Myotonic dystrophy High-grade B-cell lymphoma Primary myelofibrosis Femoral hernia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. IRCCS Humanitas Research Hospital

IRCCS Humanitas Research Hospital

Via Alessandro Manzoni 56, Rozzano, 20089, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease

    Recruiting

    2 1 1
    Investigated Drugs:
    • Humanised Igg1 Kappa Monoclonal Antibody Against Alfa4Beta7 Integrin
    • ABBV-8736
    • Risankizumab
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Study of MK-6070 drug combination in first-line extensive-stage small cell lung cancer patients

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • GOCATAMIG
    • Ifinatamab Deruxtecan
    • Atezolizumab
    France Germany Greece Italy Poland Spain

  • A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

    Recruiting

    3 1
    Austria Belgium Bulgaria France Germany Greece +4

  • Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

    Recruiting

    3 1
    Austria Belgium Bulgaria France Germany Greece +4

  • Evaluation of Anifrolumab Subcutaneous Treatment in Immunosuppressant‑Naïve and Biologic‑Naïve Patients with Systemic Lupus Erythematosus

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Anifrolumab
    France Germany Italy Poland Spain

  • Study of Tirabrutinib, Rituximab, and Temozolomide in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Rituximab
    • Temozolomide
    Austria Belgium Czechia France Germany Italy +2

  • Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

    Recruiting

    3 1
    Investigated Diseases:
    • Cardiac failure
    • Obesity
    Bulgaria Czechia Denmark France Germany Greece +4

  • A study to evaluate the effectiveness and safety of lebrikizumab in adults with nummular eczema who do not respond well to topical corticosteroids.

    Recruiting

    3 1 1
    Investigated Drugs:
    • Lebrikizumab
    Bulgaria France Germany Italy Poland Spain

  • A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic spontaneous urticaria
    Investigated Drugs:
    • Barzolvolimab
    • Epinephrine
    Belgium Bulgaria Croatia Czechia Denmark France +10

  • A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

    Recruiting

    3 1 1
    Investigated Drugs:
    • Op-1250
    • PALAZESTRANT
    • Letrozole
    Austria Belgium Czechia France Germany Greece +7
Previous Page
1 … 28 29 30 31 32 … 69
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!